Table 4. Characteristics of patients... | American Society of Hematology

Table 4.

Characteristics of patients bridging into allo-HSCT vs those not bridging into allo-HSCT after CAR T-cell therapy

Characteristic	CAR T-cell therapy followed by allo-HSCT				P
	Yes		No
	No.	%	No.	%
Sex					.47
Male	47	63	19	76
Female	28	37	8	24
Age, y					.04*
2-14	53	71	13	48
15-61	22	29	14	52
Disease status					<.001†
Relapsed after HSCT	2	3	13	48
Relapsed after chemotherapy	66	88	11	41
Primary refractory	7	9	3	11
Complex karyotypes					.69
Yes	36	48	9	33
No	36	48	14	52
Unknown	3	4	2	5
Fusion gene					.14
BCR-ABL1⁺	8	11	6	22
BCR-ABL1^–	67	89	21	78
TP53 mutation					.43
TP53⁺	7	9	4	15
TP53^–	68	91	23	85
BM blasts, %					.025*
≤20	43	57	22	81
>20	32	43	5	19
Response after CAR T-cell therapy					.7
CR	32	43	10	37
CRi	43	57	17	63
CRS grade
0-2	67	89	23	85	.985
3-4	8	11	4	15
MRD status before allo-HSCT
MRD-negative	69	92
MRD-positive	6	8
Disease status before allo-HSCT
CR1	7	9
CR2	68	91
Donor type
Matched unrelated	9	12
HLA-identical sibling	16	21
Haploidentical	50	67
HSCT conditioning regimen
Total body irradiation-based	69	92
Busulfan-based	6	8
Median days to bridge into allo-HSCT (range)	63 (36-120)

Characteristic	CAR T-cell therapy followed by allo-HSCT				P
	Yes		No
	No.	%	No.	%
Sex					.47
Male	47	63	19	76
Female	28	37	8	24
Age, y					.04*
2-14	53	71	13	48
15-61	22	29	14	52
Disease status					<.001†
Relapsed after HSCT	2	3	13	48
Relapsed after chemotherapy	66	88	11	41
Primary refractory	7	9	3	11
Complex karyotypes					.69
Yes	36	48	9	33
No	36	48	14	52
Unknown	3	4	2	5
Fusion gene					.14
BCR-ABL1⁺	8	11	6	22
BCR-ABL1^–	67	89	21	78
TP53 mutation					.43
TP53⁺	7	9	4	15
TP53^–	68	91	23	85
BM blasts, %					.025*
≤20	43	57	22	81
>20	32	43	5	19
Response after CAR T-cell therapy					.7
CR	32	43	10	37
CRi	43	57	17	63
CRS grade
0-2	67	89	23	85	.985
3-4	8	11	4	15
MRD status before allo-HSCT
MRD-negative	69	92
MRD-positive	6	8
Disease status before allo-HSCT
CR1	7	9
CR2	68	91
Donor type
Matched unrelated	9	12
HLA-identical sibling	16	21
Haploidentical	50	67
HSCT conditioning regimen
Total body irradiation-based	69	92
Busulfan-based	6	8
Median days to bridge into allo-HSCT (range)	63 (36-120)

P < 0.05.

P < 0.01.